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Is response to anti–hepatitis C virus treatment
predictive of mortality in hepatitis C virus/
HIV-positive patients?
The Hepatitis C Working Group for the Collaboration of Observational
HIV Epidemiological Research Europe (COHERE) in EuroCoordM
Background: Long-term clinical outcomes after hepatitis C virus (HCV) treatment of HIV/
HCV patients are not well described. We aimed to compare the risk of all-cause and liver-
related death (LRD) according to HCV treatment response in HIV/HCV patients in the
multicohort study Collaboration ofObservationalHIV Epidemiological Research inEurope.
Methods: All patients who had started pegylated interferonþ ribavirin (baseline) and
followed for at least 72 weeks after baseline were included. Patients were categorized
into three response groups depending on treatment duration and HCV-RNA measured
in the window 24–72 weeks after baseline. Patients who received at least 24 weeks of
therapy were defined as responders if their last HCV-RNA measured between 24 and 72
weeks after baseline was negative, and having ‘unknown response’ if HCV-RNA was
unknown. Nonresponders were treated for less than 24 weeks or were HCV-RNAþ
between 24 and 72 weeks after baseline. Mortality rates were compared using survival
analysis, and Cox regression was used to compare hazard ratios of death between
response groups.
Results: A total of 3755 patients were included: 1031 (27.5%) responders, 1639 (43.6%)
nonresponders and 1085 (28.9%) with unknown response. Rates [per 1000 person-years
of follow-up, 95% confidence interval (CI)] of all-cause death were 17.59 (14.88–20.78),
10.43 (7.62–14.28) and11.00 (8.54–14.23) for nonresponders, responders and unknown
responders, respectively. After adjustment, the relative hazard (nonresponders vs. respon-
ders) for all-cause death, LRD and nonliver-related death was 1.53 (95% CI 1.06–2.22),
3.39 (95% CI 1.32–8.75) and 1.22 (95% CI 0.80–1.84), respectively.
Conclusion: HIV/HCV patients with a favourable virological response to pegylated inter-
feronþ ribavirin had reduced risk of all-cause and LRD, whereas there was no difference in
risk of nonliver-related death when comparing responders and nonresponders.
Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Treatment with pegylated interferon (PEG-IFN) and
ribavirin (RBV) has until recently been the standard of
care for treatment of hepatitis C virus (HCV) infection.
Patients who achieve a sustained virologic response
(SVR), that is they remain HCV-RNA-negative
6 months after end of HCV treatment, are considered
virologically cured. An SVR has been shown to halt or
reverse progression of liver fibrosis [1,2], but due to the
slow evolution of liver disease in most patients, the clinical
benefit of an SVR in terms of lower risk of liver-related
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complications and death may take several years to
manifest. During that period, competing risk of death
and risk of HCV reinfection could off-set some of the
benefit of HCV therapy [3]. Furthermore, due to the
numerous adverse effects and contraindications to
interferon-based therapy, particularly in HIV-positive
persons, HCV treatment was often not offered to those
most in need of treatment [4]. Hence, an evaluation of the
clinical benefit of HCV treatment requires a large study
population and long-term follow-up.
In studies of HCV-monoinfected patients, it has been
shown that achieving an SVR is associated with a lower
risk of liver-related [5–8] and all-cause mortality [6,7].
The benefit is most pronounced for hepatic failure, and
less so for risk of hepatocellular carcinoma (HCC).
In HIV/HCV-coinfected people, the long-term clinical
outcome of HCV treatment has not been evaluated in
prospective studies of unselected patients. In a mixed
retrospective–prospective study from Spain, Berenguer
et al. [9] found that nonresponders to HCV treatment
had an almost nine-fold increased risk of liver-related
clinical events compared with patients who achieved
an SVR. Two subsequent studies from the same
group found that coinfected patients who achieved an
SVR also had a reduced risk of HIV progression and
nonliver-related death [10] and risk of all-cause
mortality and liver-related events among patients with
METAVIR F2 fibrosis or less at the time of treatment
initiation [11].
Compared with HCV-monoinfected patients, the benefit
of HCV treatment could theoretically be either greater
due to accelerated fibrosis progression in coinfected
patients or lower due to differences in the prevalence of
competing risk factors (both HIV-related and lifestyle
factors) for mortality.
The objectives of our study were to compare the long-
term risk of all-cause mortality and liver-related death
(LRD) according to response to PEG-IFN/RBV in
HIV/HCV-coinfected people enrolled in the large
prospective multicohort study Collaboration of Observa-
tional HIV Epidemiological Research in Europe
(COHERE).
Methods
Patients
COHERE (http://www.cohere.org) is a collaboration of
33 cohorts from across Europe and is part of the
EuroCoord network (www.EuroCoord.net). COHERE
was established in 2005 with the aim of conducting
epidemiological research on the prognosis and outcome
of HIV-positive persons, which the individual
contributing cohorts cannot address themselves because
of sample size or heterogeneity of specific subgroups of
HIV-positive persons. Each cohort submits data using the
standardized HIV Collaboration Data Exchange Protocol
including information on patient demographics, HBV
and HCV status and treatment, CD4þ cell counts, use of
cART, AIDS and deaths. Eighteen European cohorts
provided data for the present analysis. Our analyses were
based on data merged in July 2013.
All HCV-infected patients in COHERE who had ever
started PEG-IFN/RBVand who were followed up for at
least 72 weeks after treatment initiation were included.
Baseline is defined as the date of HCV treatment
initiation, whereas time T0 is the date 72 weeks after
treatment initiation. During most of the study period, 48
weeks of HCV treatment was standard of care for
coinfected patients. The earliest time point at which
SVR24 can be assessed would be 72 weeks after treatment
initiation for most patients.
Definitions of hepatitis C virus treatment
response
Follow-up HCV-RNA values were not reported for all
patients after end of therapy. We therefore categorized
patients into three different HCV treatment response
groups depending on HCV treatment duration and
HCV-RNA results measured in the window 24–72
weeks after baseline. Patients who received at least 24
weeks of IFN/RBV were defined as ‘responders’ if their
latest HCV-RNAmeasured in the window 24–72 weeks
after baseline was negative, and having ‘unknown
response’ if they had no HCV-RNA measured in the
week 24–72 window. Patients were defined as ‘non-
responders’ if they had received less than 24 weeks of
HCV therapy or if their latest HCV-RNA measured
the week 24–72 window after baseline was positive.
To define positive HCV-RNA values, both qualit-
ative (þ/) and quantitative measures (>615 IU/ml)
were used.
Biomarkers of fibrosis
Levels of fibrosis were determined in the time window
(6; 0) months prior to initiation of HCV treatment by
measurement of the aspartate aminotransferase-to-plate-
let ratio index (APRI) [100 (aspartate aminotransfer-
ase/upper limit of normal)/platelet count (109/l)].
Significant fibrosis (F2 on the METAVIR scale) and
cirrhosis were defined as APRI more than 1.5 and APRI
more than 2.0, respectively [12].
Statistical methods
Main characteristics of the patients are described and
compared according to whether a person was classified as
responder, nonresponder or unknown response using
chi-square or nonparametric Kruskal–Wallis tests as
appropriate.
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Three different endpoints were analysed: all-cause
mortality, LRD and nonliver-related death. Causes of
death were adjudicated individually by the participating
cohorts in COHERE. Incidence rates were calculated as
number of deaths divided by person-years of follow-up
(PYFU) at risk. Confidence intervals (CIs) around these
estimates were calculated assuming a Poisson distribution.
Mortality rates in the three groups were compared using
standard survival analysis. Survival times accrued from the
time T0 up to the date of death or last available follow-up.
In the analysis of time to cause-specific death, people who
died for other reasons were censored administratively at
the date of last follow-up according to a competing-risk
approach to analysis. People who died between baseline
and T0 were excluded. Kaplan–Meier plots have been
used to compare the cumulative risk of survival in the
three exposure groups (responders, nonresponders and
unknown response to IFN/RBV). Univariable and
multivariable Cox regression models were used to
compare hazard ratios of death between these groups
after controlling for a number of prespecified confoun-
ders. We used a manual build-up of the multivariable
models adjusting sequentially for subset of time-fixed
confounders measured at the time of IFN/RBV initiation
and grouped according to common features (e.g.
demographics, HIV-related factors and HCV-related
factors). We only included in these sets of potential
confounders factors that have been previously described
to be a common cause of treatment initiation and risk of
death, that is age, sex, origin, year of baseline, mode of
HIV transmission, prior AIDS, current CD4þ cell count,
CD4þ nadir, HIV RNA, HIV treatment at T0, HBsAg
and APRI.
Results
Baseline characteristics
We included a total of 3755 patients, who had started
HCV treatment and had at least 72 weeks of follow-up
after treatment was started (Fig. 1). Fifty-two patients had
died between the date of HCV treatment start and week
72 (T0) of follow-up. Median [interquartile range (IQR)]
duration PEG-IFN/RBV treatment was 9 (5–12)
months. Among included patients, 1031 (27.5%) were
responders, 1639 (43.6%) were nonresponders and 1085
(28.9%) had unknown HCV treatment response.
Compared with nonresponders, responders started
HCV treatment later (2007 vs. 2005), were more likely
to be MSM (31 vs. 12%) and HBsAg-positive (4.5 vs.
2.6%), had higher CD4þ cell count (455 vs. 405 cells/ml),
lower HCV-RNA levels (5.85 vs. 6.03 log10 IU/ml), less
likely to be woman (20 vs. 25%) and have a prior AIDS
diagnosis (22 vs. 27%). The median APRI score was
slightly higher among responders (0.9 vs. 0.8) (Table 1).
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Fig. 1. Selection of patients.
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Among patients with available data, the prevalence of
cirrhosis, defined as APRI more than 2.0, was 16.0%
in those with unknown response (104/650), 20.0%
in nonresponders (200/999) and 26.7% in responders
(182/681). There were no differences between the response
groups in time from baseline to assessment of APRI.
All-cause mortality according to hepatitis C virus
treatment response
After a median of 4.0 (IQR 2.0–6.5) years of follow-up
fromT0, a total of 236 deaths had occurred. One hundred
and thirty-eight (8.4%) of HCV treatment nonresponders
had died vs. 39 (3.8%) deaths among responders and 59
(5.4%) with unknown HCV treatment response. The
rates (per 1000 PYFU, 95% CI) of all-cause death were
17.59 (14.88–20.78), 10.43 (7.62–14.28) and 11.0
(8.54–14.23) for nonresponders, responders and
unknown responders, respectively.
Figure 2 shows a Kaplan–Meier plot of the cumulative
risk of all-cause mortality. For nonresponders, the 7-year
risk (95% CI) of all-cause death was 11.6% (9.5–13.7),
whereas the 7-year risk was significantly lower for
responders 8.0% (5.1–10.8) and for patients with
unknown treatment response 7.8% (5.6–10.1).
In the unadjusted Cox regression analysis, nonresponders
had a relative hazard of 1.64 (95% CI 1.15–2.34) for all-
cause death compared with responders. Results were
similar after adjusting for demographics, HIV-related
(prior AIDS, on cART at T0, current HIV-RNA and
CD4þ cell count) and hepatitis-related factors (HBsAg
and APRI) in separate models (Fig. 3). In the fully
adjusted analysis, the relative hazard (nonresponders vs.
responders) for all-cause death was 1.53 (95% CI 1.06–
2.22). In all analyses, the relative hazard for all-cause
death was NS when comparing responders with
unknown responders.
Liver-related mortality according to hepatitis C
virus treatment response
LRD accounted for a third of all deaths among
nonresponders 48 of 139 (34.8%), but only 12.8%
(5/39) among responders and 22.0% (13/59) among
patients with unknown response. The rates (per 1000
PYFU, 95% CI) of LRD were 6.12 (4.61–8.12), 1.34
(0.56–3.21) and 2.40 (1.41–4.18) for nonresponders,
responders and unknown responders, respectively.
Among the five responders who died from LRD, two had
a baseline APRI score indicating cirrhosis, one had
significant fibrosis and two had no information about
fibrosis level. One patient had evidence of HCV
reinfection, whereas the four other remained HCV-
RNA-negative during follow-up. None were diagnosed
with HCC.
The differences in risk of LRD between responders and
nonresponders were more pronounced than for all-cause
death, but the CIs were quite wide reflecting the relative
low number of LRDs in each group. The 7-year
cumulative risk of LRD was significantly higher for
nonresponders (4.2%, 95% CI 2.9–5.5) compared with
the risk for responders (1.6%, 95% CI 0.0–3.3) and for
patients with unknown treatment response (1.4%, 95%CI
0.4–2.4) (Fig. 4).
In the unadjusted Cox regression analysis, nonresponders
had a 4.43 (95% CI 1.76–11.14) increased risk of LRD
compared with responders. Again, when adjusting for
demographic, HIV-related and hepatitis-related factors,
there was little change in the incidence rate ratios (Fig. 5).
In the fully adjusted analysis, the relative hazard
(nonresponders vs. responders) of LRD was 3.39 (95%
CI 1.32–8.75).
Nonliver-related mortality according to hepatitis
C virus treatment response
A total of 34 and 90 nonliver-related deaths occurred
among responders and nonresponders, respectively. In
both groups, non-HCCmalignancy was the predominant
cause of death (5/34 and 16/90, respectively) followed by
‘unknown cause’ (5/34 and 16/90, respectively). Four
nonresponders died from AIDS, whereas there were no
AIDS-related deaths in the responder group. To
investigate whether a positive HCV treatment outcome
also results in a lower risk of nonhepatic mortality, we
repeated the analyses excluding all LRDs. In the
unadjusted analysis, there was no difference (nonrespon-
ders vs. responders) in incidence of nonliver-related death
(hazard ratio 1.23, 95% CI 0.83–1.83). Results were
similar after adjustment for demographic factors (1.19,
95% CI 0.79–1.78), HIV-related factors (1.22, 95% CI
0.81–1.82) and APRI and HBsAg status (1.35, 95% CI
0.91–2.01). In the fully adjusted model, the relative
hazard was (1.22, 95%CI 0.80–1.84). Similarly, there was
no difference when comparing responders with patients
with unknown response (results not shown).
Discussion
In this large prospective study, we included 3755 HIV/
HCV-coinfected patients, who had received PEG-IFN/
RBV. After a median of 4.0 years follow-up fromweek 72
after treatment initiation, we found that patients who had
a favourable treatment response had a significantly
improved all-cause and liver-related mortality compared
with patients who were nonresponders. Our findings
confirm the survival benefit of an SVR, shown in
previous studies of HCV-monoinfected [6,7] and HIV/
HCV-coinfected patients [9,13]. However, compared
with these studies, the improved survival in our study was
relatively modest (hazard ratio 1.53 for comparing
responders with nonresponders). In the Spanish study
by Berenguer et al. [9], which is the only other large
664 AIDS 2017, Vol 31 No 5
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observational study to include HIV/HCV-coinfected
patients from routine clinical practice, the incidence of
all-cause mortality among patients with SVR was lower
compared with the incidence among responders in our
study (0.46 vs. 1.04 per 100 PYFU), whereas the all-cause
mortality was higher among nonresponders in their study
(3.12 vs. 1.76 per 100 PYFU). The excess all-cause
mortality among nonresponders in the Spanish study
seems to be mainly explained by a high prevalence (39%)
of patients with advanced fibrosis or cirrhosis, resulting in
a high incidence of LRD among nonresponders
compared with the incidence among nonresponders
observed in our study (1.65 vs. 0.61 per 100 PYFU).
In our study, only five out of 37 deaths in the treatment
response group were from liver-related causes, and none
of them due to HCC. Two of the five patients had
evidence of cirrhosis at the time of treatment initiation,
whereas one had evidence of HCV reinfection. Other
studies have documented, that although an SVR reduces
the risk, liver-related complications can occur several
years after SVR. This is particularly the case with HCC in
patients with cirrhosis at the time of treatment [6,14].
Longer follow-up of our cohort is warranted to
determine whether the incidence of HCC and other
liver-related clinical events remains low for patients with
treatment response.
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Fig. 2. Cumulative risk of all-cause mortality in the three
hepatitis C virus treatment response groups.
Fig. 3. Adjusted hazard ratio for all-cause mortality accord-
ing to hepatitis C virus treatment response. Adjustments were
made for prespecified demographic-related, HIV-related and
hepatitis-related factors in three separate Cox regression
models as well as for all factors combined.
Fig. 4. The figure shows the cumulative risk of liver-related
death in the three hepatitis C virus treatment response
groups.
Fig. 5. The figure shows the adjusted hazard ratio for liver-
related death according to hepatitis C virus treatment response.
Adjustments were made for prespecified demographic-related,
HIV-related and hepatitis-related factors in three separate Cox
regression models as well as for all factors combined.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
As interferon is contraindicated in patients with
advanced cirrhosis due to the risk of liver decom-
pensation, it is likely that patients with more advanced
liver disease, who would have gained more clinical
benefits from HCV eradication, were excluded. It is
therefore conceivable that with the new tolerable and
effective interferon-free direct-acting antivirals (DAA),
we will be able to prevent more liver-related and,
possibly, nonliver-related complications, and this should
be addressed in further observations. Although inter-
feron-based therapy is no longer standard of care, the
data presented in this article are still of relevance to
inform the prognosis for the many patients who were
treated and cured with interferon before the arrival of
DAA. Furthermore, interferon-based therapy is still
commonly used in some countries that cannot afford
the market price of DAA. In addition, consequences of
cure are likely to be similar regardless of which
treatment was used to achieve success.
The link between chronic HCV infection and different
autoimmune and lymphoproliferative conditions, for
example mixed cryoglobulinaemia and some types of
lymphoma, is well established [15]. There is also
emerging evidence of an association between HCV
infection and risk of cardiovascular disease and other
extrahepatic diseases [15–17]. If the association is
causal, one would expect a decrease in risk of nonliver-
related death after SVR. In our study, we did not find a
lower risk of nonliver-related death among those with a
favourable HCV treatment response. This is in contrast
to a national Spanish study that found a three-fold
lower risk of nonliver-related death in HIV/HCV-
coinfected patients with SVR compared with patients
who did not achieve an SVR [10]. The reason for this
difference is not clear, but with only five and 32
nonliver-related deaths among patients with and
without SVR, respectively, the study had limited
power to investigate the question. It is possible that
some of the apparent extrahepatic health benefit of an
SVR is related to behavioural differences after
treatment and not the treatment outcome per se, as
demonstrated by a Scottish observational study of
HCV-monoinfected patients in which patients who
achieved SVR after interferon-based therapy had lower
risk of hospitalization for alcohol intoxication and
violence-related injury after treatment compared with
nonresponders to HCV treatment [18]. These findings
should be explored in other cohorts and in patients
undergoing DAA therapy.
The major strengths of this analysis are the large number
of coinfected patients recruited from a diverse geo-
graphical area throughout Europe, the long prospective
follow-up after HCV treatment and our ability to adjust
for relevant risk factors for all-cause and LRD.
However, like in all observational studies, there remains
the possibility of unmeasured confounding. Another
limitation is the lack of follow-up HCV-RNA
measurements on all patients at least 6 months after
end of therapy. In addition, some of the patients
categorized as responders could have had HCV-RNA
relapse, and some patients categorized as nonresponders
could have achieved an SVR. However, this limitation
would only tend to underestimate the survival benefit of
HCV therapy. Unexpectedly, the prevalence of cirrho-
sis, as determined by the APRI score, was higher among
responders than among nonresponders. Data to calculate
the APRI score were only available for 66 and 61% of
responders and nonresponders, respectively. If the
reason for not having an APRI score is associated
with disease status, selection bias could have been
introduced.
In conclusion, we have shown that among HIV/HCV-
coinfected patients, a favourable virological response to
HCV treatment is associated with reduced risk of both
LRD and improved overall survival in the interferon era.
Whether this holds true with the new direct-acting
antivirals remains to be investigated.
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